Vanda Pharmaceuticals' Imsidolimab Receives EMA Orphan Drug Status for GPP

Vanda Pharmaceuticals announced that its investigational drug, imsidolimab, has been granted Orphan Designation by the European Commission for Generalized Pustular Psoriasis (GPP). This designation, supported by the EMA's COMP, aims to encourage the development of treatments for rare, severe, and potentially life-threatening inflammatory skin diseases. This follows similar recognitions in the US and Japan, highlighting global efforts to address unmet medical needs for GPP patients.